Medicare Prescription Drug Fraud Prevention Act of 2019

#1505 | S Congress #116

Last Action: Read twice and referred to the Committee on Finance. (5/16/2019)

Bill Text Source: Congress.gov

Summary and Impacts
Original Text
[Congressional Bills 116th Congress]
[From the U.S. Government Publishing Office]
[S. 1505 Introduced in Senate (IS)]

<DOC>






116th CONGRESS
  1st Session
                                S. 1505

To require prescription drug plans and MA-PD plans to report potential 
 fraud, waste, and abuse to the Secretary of Health and Human Services 
             under Medicare part D, and for other purposes.


_______________________________________________________________________


                   IN THE SENATE OF THE UNITED STATES

                              May 16, 2019

Mr. Cornyn (for himself and Mr. Cardin) introduced the following bill; 
     which was read twice and referred to the Committee on Finance

_______________________________________________________________________

                                 A BILL


 
To require prescription drug plans and MA-PD plans to report potential 
 fraud, waste, and abuse to the Secretary of Health and Human Services 
             under Medicare part D, and for other purposes.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Medicare Prescription Drug Fraud 
Prevention Act of 2019''.

SEC. 2. REQUIRING PRESCRIPTION DRUG PLANS AND MA-PD PLANS TO REPORT 
              POTENTIAL FRAUD, WASTE, AND ABUSE TO THE SECRETARY OF 
              HHS.

    Section 1860D-4 of the Social Security Act (42 U.S.C. 1395w-104) is 
amended--
            (1) by redesignating subsection (m) (relating to program 
        integrity transparency measures), as added by section 6063(c) 
        of the Substance Use-Disorder Prevention that Promotes Opioid 
        Recovery and Treatment for Patients and Communities Act (Public 
        Law 115-271), as subsection (n); and
            (2) by adding at the end the following new subsection:
    ``(o) Reporting Potential Fraud, Waste, and Abuse.--Beginning 
January 1, 2021, the PDP sponsor of a prescription drug plan shall 
report to the Secretary, as specified by the Secretary--
            ``(1) any substantiated or suspicious activities (as 
        defined by the Secretary) with respect to the program under 
        this part as it relates to fraud, waste, and abuse; and
            ``(2) any steps made by the PDP sponsor after identifying 
        such activities to take corrective actions.''.
                                 <all>

AI processing bill